Impact of Supplemental Parenteral Nutrition in ICU Patients on Metabolic, Inflammatory and Immune Responses (SPN2)
Primary Purpose
Critical Illness
Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Supplemental parenteral nutrition (SPN)
Sponsored by
About this trial
This is an interventional supportive care trial for Critical Illness focused on measuring Energy requirements, Glucose turnover, Protein turnover
Eligibility Criteria
Inclusion Criteria:
- estimated duration of ICU stay > 5 days,
- estimated survival > 7 days,
- absence of contraindication to EN
- need for mechanical ventilation
- informed consent obtained from patients, close relative, or referring physician
Exclusion Criteria:
- refusal of the patient or of the next of kin
- age < 18 years
- non-functional digestive tract (short bowel, persistent ileus, proximal intestinal fistula high rate > 1.5 litres/day)
- already receiving PN before Day 3
- absence of a central venous catheter
- women who are pregnant (pregnancy test).
- Admission after cardiac arrest, or severe brain injury
Sites / Locations
- Nutrition Unit, Geneva University Hospital
- Service of Adult Intensive Care - CHUV
Arms of the Study
Arm 1
Arm 2
Arm Type
No Intervention
Experimental
Arm Label
Enteral nutrition only
Supplemental parenteral nutrition
Arm Description
Enteral nutrition to be progressed as soon as possible to energy target measured on day 3, and verified on day 4, using the usual facilitators (prokinetics)
Addition of supplemental parenteral nutrition to complete the gap between energy delivered by enteral feeding and energy target measured on day 4. Aim: 100% of this target, and not exceeding it, no catch up for energy deficit accumulated before day 4.
Outcomes
Primary Outcome Measures
Glucose and Leucine turnover
On D04:Infusion after priming of 6.6 2H2 glucose and NaH13CO3 On Day 09-10: Infusion after priming of NaH13CO3 and of L-[1-13C]-Leucine + repeat of the glucose sequence
Secondary Outcome Measures
Immune and inflammatory impact of optimized target feeding
lymphocyte phenotypes: lymphocyte subpopulations (frequency), level of activation (CD69), memory markers, effectors, regulators
Cluster differentiation CD4, CD8, and natural killer (NK) phenotypes
Cell inflammatory response (WBA and PBMC) on D4 and D10±1: IL-2, TNF-α, interleukine-6 (IL-6), IL-1, TGF, IL-10, in culture for 24 to 48h ex vivo and post stimulation by memory mix and mitogens.
Serological inflammatory response (WBA and PBMC) on D4 and D10+1: TNF-α , IL-6, C-reactive protein (CRP): ex vivo with ELISA Nosocomial infections after day 8
Full Information
NCT ID
NCT02022813
First Posted
November 25, 2013
Last Updated
February 16, 2018
Sponsor
Centre Hospitalier Universitaire Vaudois
Collaborators
University of Geneva, Switzerland
1. Study Identification
Unique Protocol Identification Number
NCT02022813
Brief Title
Impact of Supplemental Parenteral Nutrition in ICU Patients on Metabolic, Inflammatory and Immune Responses
Acronym
SPN2
Official Title
Impact of Supplemental Parenteral Nutrition (SPN) on Energy Balance, and Infection Rate in Intensive Care Patients: Underlying Metabolic, Inflammatory and Immune Mechanisms.
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
April 2014 (Actual)
Primary Completion Date
September 2016 (Actual)
Study Completion Date
June 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centre Hospitalier Universitaire Vaudois
Collaborators
University of Geneva, Switzerland
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Having previously demonstrated that supplemental parenteral nutrition to complete an insufficient enteral nutrition (EN) between D4 and D8 improves outcome after critical illness, by reducing infectious complications, the present trial aims at investigating the underlying carbohydrate and protein metabolism changes, as well as the immune and inflammatory modulations associated with this improvement.
Detailed Description
Enrollment on day 3 of critically ill patients, without contraindication to EN, not achieving 60% of the ICU per protocol energy target.
Intervention: Randomization to either continued pure EN, or from day 4 to supplemental PN to complete EN at target validated by indirect calorimetry.
Measurements: Indirect calorimetry on Days 3, 4, 9 (twice). Primary endpoints = glucose and leucine metabolism On days 4 and 9-10: isotopic investigation of glucose metabolism, and immune and inflammatory responses// Day 9-10: isotopic investigation of protein (leucine) metabolism Secondary endpoints: Insulin requirements, area under the curve (AUC) of blood Glucose, infections after day 9, overall complications, length of mechanical ventilation, of ICU and hospital stay.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Critical Illness
Keywords
Energy requirements, Glucose turnover, Protein turnover
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Enteral nutrition only
Arm Type
No Intervention
Arm Description
Enteral nutrition to be progressed as soon as possible to energy target measured on day 3, and verified on day 4, using the usual facilitators (prokinetics)
Arm Title
Supplemental parenteral nutrition
Arm Type
Experimental
Arm Description
Addition of supplemental parenteral nutrition to complete the gap between energy delivered by enteral feeding and energy target measured on day 4.
Aim: 100% of this target, and not exceeding it, no catch up for energy deficit accumulated before day 4.
Intervention Type
Dietary Supplement
Intervention Name(s)
Supplemental parenteral nutrition (SPN)
Other Intervention Name(s)
Standard industrial PN solutions
Intervention Description
The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN
Primary Outcome Measure Information:
Title
Glucose and Leucine turnover
Description
On D04:Infusion after priming of 6.6 2H2 glucose and NaH13CO3 On Day 09-10: Infusion after priming of NaH13CO3 and of L-[1-13C]-Leucine + repeat of the glucose sequence
Time Frame
10 days
Secondary Outcome Measure Information:
Title
Immune and inflammatory impact of optimized target feeding
Description
lymphocyte phenotypes: lymphocyte subpopulations (frequency), level of activation (CD69), memory markers, effectors, regulators
Cluster differentiation CD4, CD8, and natural killer (NK) phenotypes
Cell inflammatory response (WBA and PBMC) on D4 and D10±1: IL-2, TNF-α, interleukine-6 (IL-6), IL-1, TGF, IL-10, in culture for 24 to 48h ex vivo and post stimulation by memory mix and mitogens.
Serological inflammatory response (WBA and PBMC) on D4 and D10+1: TNF-α , IL-6, C-reactive protein (CRP): ex vivo with ELISA Nosocomial infections after day 8
Time Frame
10 days
Other Pre-specified Outcome Measures:
Title
Global outcome
Description
Overall complications and organ failures, length of mechanical ventilation, length of ICU and hospital stay.
Time Frame
28 days / 90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
estimated duration of ICU stay > 5 days,
estimated survival > 7 days,
absence of contraindication to EN
need for mechanical ventilation
informed consent obtained from patients, close relative, or referring physician
Exclusion Criteria:
refusal of the patient or of the next of kin
age < 18 years
non-functional digestive tract (short bowel, persistent ileus, proximal intestinal fistula high rate > 1.5 litres/day)
already receiving PN before Day 3
absence of a central venous catheter
women who are pregnant (pregnancy test).
Admission after cardiac arrest, or severe brain injury
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mette M Berger, MD PhD
Organizational Affiliation
CHUV, Lausanne
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nutrition Unit, Geneva University Hospital
City
Geneva
State/Province
GE
ZIP/Postal Code
1211
Country
Switzerland
Facility Name
Service of Adult Intensive Care - CHUV
City
Lausanne
State/Province
VD
ZIP/Postal Code
1011
Country
Switzerland
12. IPD Sharing Statement
Citations:
PubMed Identifier
23218813
Citation
Heidegger CP, Berger MM, Graf S, Zingg W, Darmon P, Costanza MC, Thibault R, Pichard C. Optimisation of energy provision with supplemental parenteral nutrition in critically ill patients: a randomised controlled clinical trial. Lancet. 2013 Feb 2;381(9864):385-93. doi: 10.1016/S0140-6736(12)61351-8. Epub 2012 Dec 3.
Results Reference
background
PubMed Identifier
30448193
Citation
Berger MM, Pantet O, Jacquelin-Ravel N, Charriere M, Schmidt S, Becce F, Audran R, Spertini F, Tappy L, Pichard C. Supplemental parenteral nutrition improves immunity with unchanged carbohydrate and protein metabolism in critically ill patients: The SPN2 randomized tracer study. Clin Nutr. 2019 Oct;38(5):2408-2416. doi: 10.1016/j.clnu.2018.10.023. Epub 2018 Nov 5.
Results Reference
derived
Learn more about this trial
Impact of Supplemental Parenteral Nutrition in ICU Patients on Metabolic, Inflammatory and Immune Responses
We'll reach out to this number within 24 hrs